id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-E-0197-0008,FDA,FDA-2024-E-0197,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2025-09-19T04:00:00Z,2025,9,2025-09-19T04:00:00Z,,2025-09-19T17:54:49Z,,0,0,09000064b8faad61
FDA-2024-E-0197-0007,FDA,FDA-2024-E-0197,Determination of Regulatory Review Period for Purposes of Patent Extension; SOHONOS,Notice,Determinations,2024-12-18T05:00:00Z,2024,12,2024-12-18T05:00:00Z,2025-02-19T04:59:59Z,2024-12-20T18:22:24Z,2024-29964,0,0,090000648687b926
FDA-2024-E-0197-0006,FDA,FDA-2024-E-0197,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2024-11-01T04:00:00Z,2024,11,2024-11-01T04:00:00Z,,2024-11-01T13:28:21Z,,0,0,09000064867ec9f5
FDA-2024-E-0197-0004,FDA,FDA-2024-E-0197,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-03-22T04:00:00Z,2024,3,2024-03-22T04:00:00Z,,2024-03-22T17:54:51Z,,0,0,090000648648d134
FDA-2024-E-0197-0003,FDA,FDA-2024-E-0197,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2024-02-09T05:00:00Z,2024,2,2024-02-09T05:00:00Z,,2024-02-09T15:35:53Z,,0,0,09000064863f7a2d
FDA-2024-E-0197-0005,FDA,FDA-2024-E-0197,Exhibit 1-9,Supporting & Related Material,Background Material,2024-01-19T05:00:00Z,2024,1,,,2024-09-18T18:46:00Z,,0,0,0900006486391be2
FDA-2024-E-0197-0002,FDA,FDA-2024-E-0197,"Patent Extension Application from CLARK & ELBING LLP (on behalf of Ipsen Biopharmaceuticals, Inc.)",Other,Application,2024-01-19T05:00:00Z,2024,1,2024-01-19T05:00:00Z,,2024-01-19T14:30:29Z,,0,0,0900006486391693
FDA-2024-E-0197-0001,FDA,FDA-2024-E-0197,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-01-19T05:00:00Z,2024,1,2024-01-19T05:00:00Z,,2024-01-19T14:30:28Z,,0,0,0900006486391691